Sugen, Inc.
Records under this name other than patents Sugen, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,230,098 | Aminoheteroaryl Compounds as Protein Kinase Inhibitors Formerly held Term ended Term ended Aug 26, 2025 · High confidence | Term ended | Term ended Aug 26, 2025 | High confidence |
| US 6,573,293 | Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors Formerly held Term ended Term ended May 22, 2023 · High confidence | Term ended | Term ended May 22, 2023 | High confidence |
| US 7,572,924 | Pyrrole Substituted 2-Indolinone Protein Kinase Inhibitors Term ended Term ended Feb 15, 2021 · Low confidence | Term ended | Term ended Feb 15, 2021 | Low confidence |
| US 7,211,600 | Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds Term ended Term ended Dec 22, 2020 · From the USPTO record | Term ended | Term ended Dec 22, 2020 | From the USPTO record |
| US 6,395,734 | Pyrrole substituted 2-indolinone protein kinase inhibitors Term ended Term ended May 28, 2019 · From the USPTO record | Term ended | Term ended May 28, 2019 | From the USPTO record |
| US 6,207,401 | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders Term ended Term ended Mar 31, 2019 · From the USPTO record | Term ended | Term ended Mar 31, 2019 | From the USPTO record |
| US 6,225,335 | 3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease Term ended Term ended Dec 15, 2018 · From the USPTO record | Term ended | Term ended Dec 15, 2018 | From the USPTO record |
| US 7,119,090 | Pyrrole substituted 2-indolinone protein kinase inhibitors Lapsed on the fee record Ended Oct 10, 2018 · From the USPTO record | Lapsed on the fee record | Ended Oct 10, 2018 | From the USPTO record |
| US 6,200,341 | Mechanical heart valve assembly with super-elastic lock wire Formerly held Term ended Term ended Sep 25, 2018 · From the USPTO record | Term ended | Term ended Sep 25, 2018 | From the USPTO record |
| US 6,841,579 | Diagnosis and treatment of AUR1 and/or AUR2 related disorders Term ended Term ended Jul 14, 2018 · From the USPTO record | Term ended | Term ended Jul 14, 2018 | From the USPTO record |